Cargando…
Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells
Ovarian cancer is the fifth leading cause of deaths due to cancer among women in the United States. In 2017, 22,440 women are expected to be diagnosed with ovarian cancer and 14,080 women will die with it. Currently used chemotherapies (Cisplatin or platinum/taxane combination) targets cancer cells,...
Autores principales: | Kakar, Sham S., Parte, Seema, Carter, Kelsey, Joshua, Irving G., Worth, Christopher, Rameshwar, Pranela, Ratajczak, Mariusz Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650357/ https://www.ncbi.nlm.nih.gov/pubmed/29088802 http://dx.doi.org/10.18632/oncotarget.20170 |
Ejemplares similares
-
Correction: Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells
por: Kakar, Sham S., et al.
Publicado: (2020) -
Verrucarin J inhibits ovarian cancer and targets cancer stem cells
por: Carter, Kelsey, et al.
Publicado: (2017) -
Withaferin A Alone and in Combination with Cisplatin Suppresses Growth and Metastasis of Ovarian Cancer by Targeting Putative Cancer Stem Cells
por: Kakar, Sham S., et al.
Publicado: (2014) -
Withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling
por: Straughn, Alex R., et al.
Publicado: (2019) -
Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors
por: Parte, Seema C., et al.
Publicado: (2018)